CompletedNCT05550532
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
This study evaluated the safety and effectiveness of Aticaprant for people with depression.
Medication studyAges 18–74Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Aticaprant for people with depression.
Who was this study for?
Listed age limits: 18 years to 74 years.
- Listed locations
- Birmingham, United States · Lafayette, United States and 104 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: December 6, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 444
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT05550532
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Recruitment & locations
CompletedBirmingham, United States · Lafayette, United States · Orange, United States
103 more locations
- Rancho Cucamonga, United States
- San Diego, United States
- Santee, United States
- Sherman Oaks, United States
- Upland, United States
- West Covina, United States
- Colorado Springs, United States
- Coral Springs, United States
- Gainesville, United States
- Hialeah, United States
- Maitland, United States
- Miami, United States
- North Bay Village, United States
- Orlando, United States
- Pompano Beach, United States
- Port Saint Lucie, United States
- Skokie, United States
- Marrero, United States
- Gaithersburg, United States
- Ann Arbor, United States
- Farmington Hills, United States
- Saint Charles, United States
- Lincoln, United States
- Buffalo, United States
- New York, United States
- Charlotte, United States
- Monroe, United States
- Cleveland, United States
- Columbus, United States
- Edmond, United States
- Oklahoma City, United States
- Allentown, United States
- Moosic, United States
- Charleston, United States
- Austin, United States
- Dallas, United States
- Stafford, United States
- Murray, United States
- Bellevue, United States
- Everett, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Rosario, Argentina
- San Miguel de Tucumán, Argentina
- Santiago del Estero, Argentina
- Curitiba, Brazil
- Porto Alegre, Brazil
- Sofia, Bulgaria
- Varna, Bulgaria
- Québec, Canada
- Sherbrooke, Canada
- Baoding, China
- Beijing, China
- Changsha, China
- Chengdu, China
- Guangzhou, China
- Huzhou, China
- Shanghai, China
- Shijiazhuang, China
- Suzhou, China
- Tianjin, China
- Wuhan, China
- Wuhu, China
- Xi'an, China
- Zhengzhou, China
- Brno, Czechia
- Kutná Hora, Czechia
- Prague, Czechia
- Bohars, France
- Clermont-Ferrand, France
- Douai, France
- Nantes, France
- Paris, France
- Tours, France
- Bydgoszcz, Poland
- Katowice, Poland
- Poznan, Poland
- Suchy Las, Poland
- Banská Bystrica, Slovakia
- Bojnice, Slovakia
- Bratislava, Slovakia
- Košice, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Vranov nad Topľou, Slovakia
- Cape Town, South Africa
- Pretoria, South Africa
- Strand, South Africa
- Bucheon-si, South Korea
- Busan, South Korea
- Goyang, South Korea
- Gyeonggi-do, South Korea
- Seoul, South Korea
- Taichung, Taiwan
- Taipei, Taiwan
- Brighton, United Kingdom
- Edinburgh, United Kingdom
- London, United Kingdom
- Paisley, United Kingdom
- Southampton, United Kingdom
- Wigan and Leigh, United Kingdom
- Czechia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Aticaprant for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Aticaprant.
Who was this study for?
Listed age limits: 18 years to 74 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me